Furthermore, approximately 90% of CHL cases exhibit JAK/STAT pathway dysregulation caused by alterations in multiple genes, including JAK1, JAK2, STAT3, and STAT5B, supporting a pivotal role of this pathway in CHL [32]. This evidence concerns the gene JAK1 and classic Hodgkin lymphoma.